A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in Their Tumor DNA
Status:
Recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test whether the study drug, niraparib, is effective against
unresectable and/or metastatic soft tissue sarcoma with DDR mutations. The researchers will
also study whether niraparib is safe and causes few or mild side effects, and whether there
are groups of DDR mutations in soft tissue sarcoma cells that respond better to treatment
with niraparib.